Today, 398,970 doses of the safe and effective Pfizer COVID-19 arrived in Madagascar. These vaccines were delivered via the COVAX facility and are part of the Biden-Harris Administration’s global effort to rapidly increase vaccine coverage and end this pandemic.
“Widespread vaccination is the most important step we can take to ensure a return to normal life as soon as possible,” United States Agency for International Development (USAID) Madagascar Mission Director John Dunlop said in an arrival ceremony at Ivato Airport. “Please do what you can and get vaccinated,” he added.
This is the third vaccine donation to Madagascar from the American people. The United States donated 302,750 doses of the Johnson&Johnson COVID-19 vaccine in July and an additional 336,000 Johnson&Johnson doses in October from the U.S. domestic supply.
“The United States will be the world’s arsenal of vaccines in our shared fight against this virus,” President Biden said in a June 3 statement.
The United States is sharing vaccine doses with nearly all African countries to save lives and to lead the world in bringing an end to the pandemic. This effort is just one more example of our commitment to our African partners as we confront new waves of the pandemic.
In Madagascar, USAID has provided $5.1 million to support health care facilities and increase vaccine access as well as $2.5 million to assist with the delivery and rollout of vaccines, expand infectious disease testing, and provide personal protective equipment for health workers. The Peace Corps is also supporting the Government of Madagascar’s vaccination efforts by helping to vaccinate more than 25 percent of all eligible residents in the commune of Mantasoa.
The United States is working closely with the Government of Madagascar, like “mpirahalahy mianala,” to protect public health, and we will continue to do all we can to build a world that is safer and more secure against the threat of infectious disease.
Distributed by APO Group on behalf of U.S. Embassy in Madagascar&Comoros.
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
